Revenue: As of FY2026 Q2, the actual value is USD 6.976 M.EPS: As of FY2026 Q2, the actual value is USD 0.EBIT: As of FY2026 Q2, the actual value is USD 190 K.<h3>Segment Revenue</h3><ul><li>Packaged Sales: Astaxanthin packaged sales were $3,265,000 for the three months ended September 30, 2025, compared to $3,119,000 for the same period in 2024, representing a 4.7% increase. Spirulina packaged sales were $1,308,000 compared to $1,087,000, a 20.3% increase.</li><li>Bulk Sales: Astaxanthin bulk sales were $1,533,000 for the three months ended September 30, 2025, compared to $632,000 for the same period in 2024, representing a 142.6% increase. Spirulina bulk sales were $826,000 compared to $710,000, a 16.3% increase.</li><li>Contract Extraction and R&amp;D Services: Revenue was $44,000 for the three months ended September 30, 2025, compared to $297,000 for the same period in 2024, representing an 85.2% decrease.</li></ul><h3>Operational Metrics</h3><ul><li>Net Income: Net income for the three months ended September 30, 2025 was $1,000, compared to a net loss of - $1,150,000 for the same period in 2024.</li><li>Gross Profit: Gross profit was $2,393,000 for the three months ended September 30, 2025, compared to $1,479,000 for the same period in 2024, representing a 34.3% gross profit margin compared to 25.3% in 2024.</li><li>Operating Expenses: Operating expenses were $2,203,000 for the three months ended September 30, 2025, compared to $2,454,000 for the same period in 2024, representing a decrease of $251,000.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: Net cash used in operating activities was - $220,000 for the six months ended September 30, 2025, compared to - $201,000 for the same period in 2024.</li><li>Investing Cash Flow: Net cash used in investing activities was - $86,000 for the six months ended September 30, 2025, compared to - $105,000 for the same period in 2024.</li><li>Financing Cash Flow: Net cash provided by financing activities was $698,000 for the six months ended September 30, 2025, compared to $379,000 for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: Cyanotech Corporation aims to stabilize production volume, rationalize market channel participation, and leverage its centers of core competence. The company will continue to emphasize Nutrex Hawaiian consumer products while exploring further opportunities for bulk sales orders for spirulina and astaxanthin, both domestically and internationally.</li><li>Non-Core Business: The company plans to generate additional income through extraction services to third-party customers utilizing its supercritical carbon dioxide extractor process.</li><li>Priority: The company will focus on higher margin consumer products that promote health and well-being and strive for continuous improvements in processes and production methods to stabilize costs and production levels for the future.</li></ul>

CYAN

Cyanotech | 10-Q: FY2026 Q2 Revenue: USD 6.976 M